145 related articles for article (PubMed ID: 31160603)
1. EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression.
Yoon S; Choi JH; Kim SJ; Lee EJ; Shah M; Choi S; Woo HG
Exp Mol Med; 2019 Jun; 51(6):1-12. PubMed ID: 31160603
[TBL] [Abstract][Full Text] [Related]
2. A paradigm shift in EPH receptor interaction: biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines.
Fox BP; Kandpal RP
Cancer Genomics Proteomics; 2011; 8(4):185-93. PubMed ID: 21737611
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel reversed trastuzumab resistance via regulating JUN in human gastric cancer cells identified by FAN analysis.
Wang Z; Zou F; Tian Y; Xiang B; Qin B; Liu Y
Future Oncol; 2018 Nov; 14(26):2701-2712. PubMed ID: 30265158
[TBL] [Abstract][Full Text] [Related]
5. Modulation of liver-intestine cadherin (Cadherin 17) expression, ERK phosphorylation and WNT signaling in EPHB6 receptor-expressing MDA-MB-231 cells.
Bhushan L; Tavitian N; Dey D; Tumur Z; Parsa C; Kandpal RP
Cancer Genomics Proteomics; 2014; 11(5):239-49. PubMed ID: 25331796
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
[TBL] [Abstract][Full Text] [Related]
7. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
8. EphB6 overexpression and Apc mutation together promote colorectal cancer.
Xu D; Yuan L; Liu X; Li M; Zhang F; Gu XY; Zhang D; Yang Y; Cui B; Tong J; Zhou J; Yu Z
Oncotarget; 2016 May; 7(21):31111-21. PubMed ID: 27145271
[TBL] [Abstract][Full Text] [Related]
9. EphB6 promotes anoikis by modulating EphA2 signaling.
Akada M; Harada K; Negishi M; Katoh H
Cell Signal; 2014 Dec; 26(12):2879-84. PubMed ID: 25239188
[TBL] [Abstract][Full Text] [Related]
10. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.
Loessner D; Quent VM; Kraemer J; Weber EC; Hutmacher DW; Magdolen V; Clements JA
Gynecol Oncol; 2012 Dec; 127(3):569-78. PubMed ID: 22964375
[TBL] [Abstract][Full Text] [Related]
11. Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.
Aldonza MBD; Ku J; Hong JY; Kim D; Yu SJ; Lee MS; Prayogo MC; Tan S; Kim D; Han J; Lee SK; Im SG; Ryu HS; Kim Y
Sci Adv; 2020 Feb; 6(6):eaav7416. PubMed ID: 32083171
[TBL] [Abstract][Full Text] [Related]
12. EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
Toosi BM; El Zawily A; Truitt L; Shannon M; Allonby O; Babu M; DeCoteau J; Mousseau D; Ali M; Freywald T; Gall A; Vizeacoumar FS; Kirzinger MW; Geyer CR; Anderson DH; Kim T; Welm AL; Siegel P; Vizeacoumar FJ; Kusalik A; Freywald A
Oncogene; 2018 Jul; 37(30):4073-4093. PubMed ID: 29700392
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
14. Pygopus2 inhibits the efficacy of paclitaxel-induced apoptosis and induces multidrug resistance in human glioma cells.
Zhou C; Cheng H; Qin W; Zhang Y; Xiong H; Yang J; Huang H; Wang Y; Chen XZ; Tang J
Oncotarget; 2017 Apr; 8(17):27915-27928. PubMed ID: 28427190
[TBL] [Abstract][Full Text] [Related]
15. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
16.
Pu J; Shen J; Zhong Z; Yanling M; Gao J
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):639-647. PubMed ID: 32064933
[TBL] [Abstract][Full Text] [Related]
17. The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.
Truitt L; Freywald T; DeCoteau J; Sharfe N; Freywald A
Cancer Res; 2010 Feb; 70(3):1141-53. PubMed ID: 20086179
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK).
Lee LF; Li G; Templeton DJ; Ting JP
J Biol Chem; 1998 Oct; 273(43):28253-60. PubMed ID: 9774447
[TBL] [Abstract][Full Text] [Related]
19. EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer.
Peng Q; Chen L; Wu W; Wang J; Zheng X; Chen Z; Jiang Q; Han J; Wei L; Wang L; Huang J; Ma J
Cell Death Dis; 2018 Nov; 9(12):1146. PubMed ID: 30451837
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of microRNA-16 facilitates the paclitaxel resistance by targeting IKBKB via NF-κB signaling pathway in hepatocellular carcinoma.
Huang Y; Chen G; Wang Y; He R; Du J; Jiao X; Tai Q
Biochem Biophys Res Commun; 2018 Sep; 503(2):1035-1041. PubMed ID: 29935185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
